Rosuvastatin provides superior CV benefits and lower mortality than atorvastatin in diabetic patients.

Statins are the standard first-line treatment for lowering cholesterol and the risk of cardiovascular (CV) diseases.¹ However, for statin-intolerant patients, discontinuation of therapy is often linked to an increased risk of adverse CV events.¹ 

Atherosclerotic cardiovascular disease (ASCVD) continuesto be a leading cause of morbidity and mortality worldwide,with over 17.9 million people dying from cardiovascular (CV)diseases annually.1,2 Given the fact that the recurrent riskis high among patients with established ASCVD, secondarypreventio

A newly published clinical practice guideline in the Journal of Clinical Endocrinology & Metabolism provided the latest evidence-based guidance on the management of dyslipidemia and the reduction of atherosclerotic cardiovascular disease (ASCVD) risk in patients with various kinds of endocrine disea

The Journal of the American College of Cardiology has recently published a study showing that the addition of a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor evolocumab to a maximally tolerated dose of statin medication has no adverse impact on patient-reported